Zhitong Finance App News, Deqi Pharmaceutical-B (06996) announced that Mr. Long Zhenguo has proposed to resign as an executive director and chief financial officer of the Company in order to seek other career development opportunities, effective August 1, 2026.

Dr. Hou Bing has been appointed as an Executive Director with effect from August 1, 2026.

Ms. Guo Rui has been appointed as the Chief Commercial Officer of the Company with effect from August 1, 2026.

Following Mr. Sui Lung's resignation as an executive director, Mr. Lung will also cease to act as the Company's authorized representative under section 3.05 of the Listing Rules and the Company's authorized representative to receive legal process documents and notices on behalf of the Company in Hong Kong under section 19.05 (2) of the Hong Kong Rules, with effect from August 1, 2026.

Dr. Hou has been appointed as an authorized representative with effect from August 1, 2026.

Meanwhile, Mr. Qiu Yijun has been appointed as an agent for legal proceedings with effect from August 1, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.